Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $22.04 USD
Change Today -0.39 / -1.74%
Volume 50.0K
MNTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:13 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

675 West Kendall Street

Cambridge, MA 02142

United States

Phone: 617-491-9700

Fax: 617-621-0431

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease. Programs Enoxaparin Sodium Injection—Generic Lovenox Enoxaparin Sodium Injection, the company’s only approved product, is a generic version of Lovenox. Lovenox is a low molecular weight heparin (LMWH), used for the prevention and treatment of deep vein thrombosis (DVT), and to support the treatment of acute coronary syndromes (ACS). Lovenox is marketed in the United States by Sanofi-Aventis. The company’s Enoxaparin Sodium Injection was developed and is being commercialized in the United States in collaboration with Sandoz AG and Sandoz Inc. (together as Sandoz). The company’s Enoxaparin Sodium Injection was approved by the United States Food and Drug Administration (FDA) in syringe form in 2010 and in vial form in 2011. M356—Generic Copaxone (glatiramer acetate injection) Candidate M356 is being developed as a generic version of Copaxone. Copaxone, a complex drug consisting of a synthetic mixture of polypeptide chains, is indicated for treatment of patients with relapsing-remitting multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. Copaxone is marketed in the United States by Teva Neuroscience, Inc., a subsidiary of Teva Pharmaceutical Industries, Ltd. M356 is being developed and commercialized in the United States in collaboration with Sandoz. The company is responsible for certain development activities and Sandoz is responsible for commercialization of M356. Biosimilars M923—Biosimilar HUMIRA (adalimumab) Candidate M923 is being developed as a biosimilar of HUMIRA. HUMIRA is a monoclonal antibody that can bind to a substance in the body known as tumor necrosis factor (TNF), thereby inhibiting the known effect of TNF as a potent mediator of inflammation. HUMIRA is indicated for the treatment of patients with rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis, among other diseases, who have had an inadequate response to certain other currently available treatments. HUMIRA is marketed globally by AbbVie. M923 is being developed and commercialized in collaboration with Baxter. The company is responsible for development activities through submission of an Investigational New Drug application, to the FDA, or equivalent application in the EU, and Baxter is responsible for clinical development, manufacturing and commercialization activities. In 2014, a clinical trial application (CTA), to initiate a pharmacokinetic clinical trial for M923 was accepted by the UK Medicines and Healthcare Products Regulatory Agency. Biosimilar ORENCIA (abatacept) Candidate M834 is being developed as a biosimilar of ORENCIA. ORENCIA is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4 that inhibits an immune response by blocking certain T cell signals. ORENCIA is indicated for the treatment of patients with rheumatoid arthritis and juvenile idiopathic arthritis who have had an inadequate response to certain other available treatments. ORENCIA is marketed globally by Bristol-Myers Squibb and co-promoted by Ono Pharmaceutical in Japan. The company retains all worldwide development and commercialization rights for M834. Other Biosimilar Programs The company is investing in various other, earlier stage biosimilar programs. Novel Therapeutics Necuparanib—Oncology Product Candidate Necuparanib is a novel oncology product candidate derived from heparin and engineered to have a broad range of potential effects on tumor cells and the environment in which tumor cells grow. In June 2014, necuparanib received Orphan Drug Designation from the U.S. FDA for the treatment of pancreatic cancer. In December 2014, the company received Fast-Track designation by the FDA for necuparanib as a first-line treatment in combination with Abraxane and gemcitabine in patients with metastatic pancreatic cancer. In 2014, the company initiated Part B, or Phase 2, of the Phase 1/2 t

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $22.04 USD -0.39

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amarin Corp PLC $2.24 USD +0.091
Amphastar Pharmaceuticals Inc $16.46 USD -0.05
OraSure Technologies Inc $5.12 USD -0.12
SciClone Pharmaceuticals Inc $9.15 USD -0.21
Sucampo Pharmaceuticals Inc $21.98 USD -0.73
View Industry Companies
 

Industry Analysis

MNTA

Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.9x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit www.momentapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.